Abolib (Apelis) inclusion in medical insurance in 2024

Abolibib, also known as Apelvis, is a drug that has shown significant efficacy in the treatment of breast cancer, especially in the treatment of breast cancer with PIK3CA mutations. Its effect has attracted much attention. However, for many patients, the question of whether Abolib can be included in medical insurance has always been the focus of their attention.

Since abolib has not yet been approved by the China Food and Drug Administration and marketed, it is still missing from the Chinese market. This means that for domestic patients, they are temporarily unable to purchase this drug in domestic hospital pharmacies or pharmacies. The drugs covered by medical insurance are all drugs on the domestic market. Since Abolib is not marketed in China, it is naturally not included in China's medical insurance drug list. This means that patients who need Abolib treatment cannot enjoy the benefits of medical insurance reimbursement in the country.

For patients who need abolib treatment, they need to purchase it from overseas regular channels. It is reported that the market price of the European version of the original drug Abolibib produced by the Swiss company Novartis is approximately more than 40,000 yuan. Each box contains 56 tablets, each with a specification of 150 mg. At the same time, there is an Indian original version of Apelvis on the market that is relatively more affordable. The price is about 5,000 yuan. Each box contains 28 tablets, and each tablet has the same specification of 150 mg. In addition, a generic version of the drug produced by Lucius is also available on the Laotian market. The price is more affordable. Each box is priced at about 2,000 yuan. The specification is also 150mg*28 tablets, providing more economic options for patients in need of treatment.

Although Abolibib has not yet been included in China's medical insurance drug list, it is believed that with the advancement of medical technology and the continuous development of drug research and development, Abolibib is expected to be launched in China and included in the scope of medical insurance, bringing treatment hope to the majority of patients.